Navigation Links
La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert

La Jolla Pharmaceutical value debate is raging on as investors consider the facts in the merger agreement with Adamis Pharmaceuticals Corp. Some investors have stated in a TapeBeat.Com discussion thread that the value is to be decided by the market while other say simple math proves the value was set in the merger agreement.

New York, NY (PRWEB) December 10, 2009 -- TapeBeat.Com the news and research portal for the serious investor has noted an extreme range of disagreement among investors and traders about the value of La Jolla Pharmaceutical Company (LJPC) and Adamis Pharmaceuticals Corp (ADMP). To say it's a disagreement is putting it mildly. Some investors have been clearly inferring it would be better to let the stock fly even if simple math may prove the value set at a much lower range and leave 'others holding the bag'. Traders at TapeBeat.Com freely share information and research and would like the facts, whatever they are, brought to light and to make sure full due diligence is available to all. A discussion thread was started on TapeBeat.Com which spilled over into other boards where some put the value of La Jolla between .04 and .07 (xluckystrike21 and others). LJPC closed at .25 in after hours trading after a 2 day run up of about 280%. So is the value less than a dime or more than a quarter for La Jolla (LJPC). Could it be possible that so many are wrong and the better value is to buy Adamis Pharmaceuticals Corp (ADMP) shares?

The discussion thread that was started on the La Jolla Pharmaceutical Company (LJPC) Merger with Adamis Pharmaceuticals Corp (ADMP) begins:

People have it is a REVERSE MERGER- ADMP is merging into and becoming LJPC. In reverse mergers, a company with no business merges with a company who has business.....LPJC has not business but ADMP does. All LPJC has is NET $3MM in cash and nothing else. As in all reverse mergers, the surviving merged company issues stock to complete the merger. In this merger, regardless of what the market price is, the PPS for LJPC is the $3 million divided by the number of LJPC shares (66 million + 4 million options=70 million). So the most LJPC shares are worth in the merger is about 4-5 cents. LJPC is first performing a reverse stock split to match prices with ADMP. S0 if ADMP is at about 25 cents, its average for the last several months, LJPC shareholders will at least a 5:1 reverse split for the adjusted share price, and get ONE share in the new company. Current ADMP shareholders will also get one share in the company. In the end, LPJC shareholders will only own 10-20% of the company. So at the current LJPC share price, they will see about a NEGATIVE 80% return on their investment... to continue reading the discussion thread visit TapeBeat.Com.

This information was compiled by TapeBeat.Com staff writers with no trading in either stock. TapeBeat.Com is not associated with either company and has received no incentive to disseminate this information, which is the opinion of the poster.

TapeBeat.Com is the place for the serious investor, who wishes to make "Each Trade Better". This is accomplished by a sharing of research and trading strategies with an experienced group of investors. The TapeBeat portfolio is one of the highest ranked on Covestor and is an example of the results that are attainable through the 'free sharing' of information that occurs on TapeBeat.Com. Sign up now to receive important trading alerts for free, or to share your research and opinions.

By viewing information from TapeBeat.Com you agree to our disclaimer.


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related biology technology :

1. La Jolla Institute for Allergy & Immunology Wows With New Website
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Heritage and Ipca Enter Into Strategic Alliance for Generic Pharmaceutical Products
Post Your Comments:
Related Image:
La Jolla Pharmaceutical Company - Value Play or Overvalued: TapeBeat.Com Trader Alert 
(Date:11/24/2015)... 24, 2015  Twist Bioscience, a company focused ... Ph.D., Twist Bioscience chief executive officer, will present ... December 1, 2015 at 3:10 p.m. Eastern Time at The ... --> --> ... Bioscience is on Twitter. Sign up to follow ...
(Date:11/24/2015)... , Nov. 24, 2015 Capricor Therapeutics, ... focused on the discovery, development and commercialization of first-in-class ... Chief Executive Officer, is scheduled to present at the ... at 10:50 a.m. EST, at The Lotte New York ... . . --> ...
(Date:11/24/2015)... , Nov. 24, 2015 According to two new ... 2005. This is something that many doctors, scientists, and public ... questions remains: with fewer PSA tests being done, will there ... Dr. David Samadi, "Despite the efforts made ... remains the second leading cancer cause of death in men, ...
(Date:11/23/2015)... ... 23, 2015 , ... Noblis, Inc., a leading provider of science, technology, and ... Geospatial Intelligence Agency (NGA), has joined the Noblis NSP team as President of the ... intelligence community and the private sector,” said L. Roger Mason, Jr., Ph.D. , ...
Breaking Biology Technology:
(Date:11/18/2015)... -- As new scientific discoveries deepen our understanding of how ... face challenges in better using that knowledge to guide ... more children continue to survive pediatric cancer, that counseling ... John M. Maris, M.D ., a pediatric ... . --> John M. Maris, M.D ...
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/12/2015)... 12, 2015  Arxspan has entered into an ... Harvard for use of its ArxLab cloud-based suite ... The partnership will support the institute,s efforts to ... research information internally and with external collaborators. The ... managing the Institute,s electronic laboratory notebook, compound and ...
Breaking Biology News(10 mins):